Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1500Source: DataRank Database

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects is a research paper published in Cancer Discovery (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.77)OA: closedTopics (48)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

David S.P. Tan ORCID,Anastasios Stathis ORCID,Geoffrey I. Shapiro ORCID,Satoru Iwasa ORCID,Markus Joerger ORCID

Live enrichment

PubMed:40516108 OpenAlex:https://openalex.org/W4411300972

National Institutes of Health

Grant: 1R01CA255074-01

Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors

U.S. Department of Defense

Grant: W81XWH-21-1-0282

U.S. Department of Defense

Grant: W81XWH-21-1-0502

Bayer (Bayer AG)

Bayer

Bayer (Bayer AG)

FWCI

2.77

Citation Percentile

0.9%

Citation Trend

2025

2026

closed

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-24-1500/3621607/cd-24-1500.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-24-1500/3638217/cd-24-1500.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/15/10/2019/3655797/cd-24-1500.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-24-1500

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40516108

Fields of Study

DNA Repair MechanismsCell death mechanisms and regulationPARP inhibition in cancer therapy03 medical and health sciences0302 clinical medicineHumansFemaleMaleNeoplasmsMiddle AgedDNA DamageAgedAtaxia Telangiectasia Mutated ProteinsAdultAged, 80 and over

MeSH Terms

AdultAgedAged, 80 and overDNA DamageFemaleHumansMaleMiddle AgedNeoplasmsAtaxia Telangiectasia Mutated Proteins

Keywords

DNA damageDNASchedulePhase (matter)Maximum tolerated doseCancer researchComputational biologyMedicineBiologyChemistryClinical trialGeneticsInternal medicineComputer scienceMaleAdultAged, 80 and overNeoplasmsHumansFemaleAtaxia Telangiectasia Mutated ProteinsMiddle AgedAged